How MDs are discussing migraine treatment options with patients Since 2018, the migraine treatment landscape has changed dramatically, with two new approvals in the month of February alone (Vyepti, Nurtec ODT). In light of these developments, we were curious about how migraine
COVID-19: Impact on Healthcare Practices and Treatment Decisions The evolving COVID-19 pandemic is causing enormous impact on individuals and the healthcare system. Increasingly, it is also clear that COVID-19 has broad-ranging effects on our workplaces, our economy, and our social interactions.
AAN 2020 Abstracts Released - What We're Watching in Multiple Sclerosis As of March 13, the AAN annual meeting has been cancelled due to the ongoing global COVID-19 (Coronavirus) pandemic. We'll be keeping a close eye on any plans to hold events digitally and
Treating migraine was a major topic at AAPM 2020 - Here’s how migraine treaters perceive the anti-CGRPs While opioid abuse deterrence and deprescribing topics were again center stage at the American Academy of Pain Medicine (AAPM) Annual Meeting this year—held February 26-March 1 in National Harbor, MD—headache and
Embracing Agility in Pharma Market Research The following is based on a presentation given by ZoomRx at the Pharma Market Research Conference in Newark, NJ on Feb 5-6, 2020. Please reach out via the form at the bottom of
Rare is Everywhere: How 5 Lessons from Rare-disease Market Research Apply to Patient Segments in Common Diseases The continued growth of personalized medicine and other treatment trends presents new challenges for market researchers. Within patient populations that were once considered relatively homogenous, new, smaller patient subgroups are being identified as
ASH 2019: Hem-oncs share their perspective on the latest in MM and CLL treatment among other key topics Nearly 30,000 hematology specialists gathered for this year’s 2019 American Society of Hematology (ASH) annual meeting held Dec 7-10 in Orlando, Florida. This year’s conference delivered on its promise to
Getting ready for ASH 2019: Perspective from the ZoomRx hem-onc panel The ASH 2019 Annual Meeting kicks-off this Saturday (12/7) in Orlando. Our survey of 51 practicing hematologists-oncologists indicated a great deal of excitement and anticipation, as they prepare for the meeting.In
Cardiologists share their perspective on The Medicines Co.'s inclisiran and other key events from AHA's 2019 Scientific Sessions Following AHA 2019 Scientific Sessions, Novartis announced its intention to buy The Medicines Company for nearly $10B, based on promising results on its small interfering RNA (siRNA) therapy, inclisiran.The therapy targets PCSK9
JAKs continue to capture attention, new MOAs stir excitement at ACR 2019 This year’s annual meeting held November 8-13 did not disappoint according to a ZoomRx survey with 35 rheumatologists who attended the conference.
Associate Principal Kat Lynch on working in a team-based environment and appreciating malaise-era cars. Kat Lynch is an Associate Principal in our Boston office. She’s been at ZoomRx for over three years and has worked in pharma market intelligence for over 20. Kat’s deep understanding
Oncologists on ESMO 2019 and the Potential Impact of Key PARP Inhibitor Data Following this year’s ESMO annual meeting we asked a group of oncologists practicing in the US to weigh in on Europe’s biggest oncology conference. Oncologists expressed general excitement about the meeting,
Evaluating Print vs. Digital Aids in Oncology Equipping reps with digital visual aids is a time and cost-intensive exercise. Consequently, sales leadership teams find themselves grappling with the questions:The conventional logic is that digital aids enable sales reps to
We’ve tracked oncology promotional efforts for 120+ brands across 60,000 interactions over the last 5 years. Oncology sales forces are complex and nuanced. They carry multiple products and indications, often conveying multiple themes in the same interaction, given the breadth of indications a typical oncologist treats. As a result, an oncology interaction is a prioritization exercise...
Giving Back by Taking a Survey The most rewarding part of the ZoomRx research experience is successfully funding the treatment of a deserving patient.Healthcare professionals (HCPs) are busy. The decision to participate in research is always a trade-off
Oncologists reflect on ASCO 2019 The data shared at this year's ASCO Annual Meeting moved the field of clinical oncology forward.Our survey with over 60 oncologists who attended the conference shows that ASCO 2019 did not disappoint.
ZoomRx, MGH, and the Sumaira Foundation Collaborate on Newly Published NMO Research When approached by the Global Neurology Research Group at Mass General Hospital (along with the Sumaira Foundation) with the opportunity to collaborate on a global study of neuromyelitis optica (NMO), we were eager
Practicing Oncologists Weigh In on ASCO's 2019 Annual Meeting With ASCO just days away, oncologists are divided in their outlook for this year's meeting. In our survey of 54 practicing oncologists who plan on attending the conference, half (52%) reported they expect
Breakthrough Treatments and Pharma's Pricing Dilemma - Perspective from AAN 2019 The recent 2019 AAN conference (May 4-10, Philadelphia) brought promising new data in rare diseases, generating a great deal of excitement and anticipation for new therapies.
ZoomRx Teams Up with Health Care Without Walls Under the direction and vision of Dr. Roseanna Means, Health Care Without Walls (HCWW) has been working to provide care to homeless women and families in the greater Boston area for nearly two decades.
Welcome to Our Blog We believe there is important work to be done at the intersection of healthcare, technology, and data. This blog will chronicle some of that work being done at ZoomRx and by others.
